Far East Pharmaceutical (00512.HK) showcases innovative achievements again, significantly consolidating its leading position in nuclear medicine for the diagnosis and treatment of cancer. The Go Global strategy solidifies its leading position as a multinational corporation in the field of nuclear medicine.

According to the Securities Times APP, the recent Pujiang Urological Tumor Academic Conference and Shanghai Anticancer Association Urological Tumor Special Committee Annual Meeting was held in Shanghai. Top experts in the field of urological tumors from domestic and foreign countries gathered together. Uni-Bio (00512.HK) released the "Urinary Tract Epithelial Cancer Early Screening and Early Diagnosis Project" at the meeting, and also delivered a special report on "Precision Diagnosis and Treatment of Urinary Tract Epithelial Cancer and Development of Nuclear Medicine for Urological Tumors", showcasing the company's systematic layout and research strength in early screening, early diagnosis, precision diagnosis and treatment, and innovation in nuclear medicine.